+86-400-890-9989
Product Catalog
> JNK2 Protein & Antibody (MAPK9) JNK2 Protein & Antibody (MAPK9)
c-Jun N-terminal Kinase 2 (Mitogen-Activated Protein Kinase 9)
JNK2 Products
JNK2 Protein, Recombinant
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| JNK2/MAPK9 | Human | JNK2/MAPK9 Protein, Recombinant | 10745-H08B |
JNK2 Antibody
| Molecule | Application | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| Human JNK2/MAPK9 |
WB, ELISA | JNK2/MAPK9 Antibody, Mouse MAb | 10745-MM01 |
| Human JNK2/MAPK9 |
WB, ELISA | JNK2/MAPK9 Antibody, Rabbit PAb | 10745-RP01 |
| Human JNK2/MAPK9 |
WB, ELISA | JNK2/MAPK9 Antibody, Rabbit PAb (Antigen Affinity Purified) | 10745-RP02 |
| Human JNK2/MAPK9 |
WB, ELISA | JNK2 / MAPK9 Antibody | 10745-R004 |
| Human JNK2/MAPK9 |
WB, ELISA, IHC-P | JNK2 / MAPK9 Antibody | 10745-R011 |
JNK2 cDNA Clone
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| JNK2/MAPK9 | Human | Homo sapiens JNK2/MAPK9 cDNA Clone(NM_002752.4) | HG10745-M |
JNK2 Related Areas
Enzyme>>Protein Kinase>>Intracellular Kinase>>Mitogen-Activated Protein Kinase (MAPK)>>JNK2/MAPK9
Neuroscience>>Axon Guidance>>Wnt Signaling Pathway>>JNK2/MAPK9
Signal Transduction>>Protein Kinase>>Intracellular Kinase>>Mitogen-Activated Protein Kinase (MAPK)>>JNK2/MAPK9
Signal Transduction>>Wnt Signaling Pathway>>Non-Canonical Wnt Pathway>>JNK2/MAPK9
Stem Cell>>Wnt Signaling Pathway>>Non-Canonical Wnt Pathway>>JNK2/MAPK9
JNK2 Alternative Names
JNK2, MAPK9, JNK2A, JNK2ALPHA, JNK2B, JNK2BETA, PRKM9, p54aSAPK, SAPK, stress-activated protein kinase JNK2, p54a, NK-55 [Homo sapiens]
JNK2, Mapk9, Prkm9, p54aSAPK, JNK/SAPK alpha, stress-activated protein kinase JNK2, RP23-10G21.6, AI851083 [Mus musculus]
JNK2 Related Products
Protein Products
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! |
| ERK2/MAPK1/MAPK2 | Human | ERK2/MAPK1 Protein, Recombinant, With GST Tag |
| JNK1/MAPK8 | Human | JNK1/MAPK8 Protein, Recombinant |
| p38 delta/MAPK13 | Human | p38 delta/MAPK13 Protein, Recombinant, with GST Tag |
| p38 alpha/MAPK14 | Human | p38 alpha/MAPK14 Protein, Recombinant |
| p38 alpha/MAPK14 | Human | p38 alpha/MAPK14 Protein, Recombinant |
| p38 alpha/MAPK14 | Human | p38 alpha/MAPK148 Protein, Recombinant |
| MAPKAPK3 | Human | MAPKAPK3 Protein, Recombinant |
cDNA Clone Products
JNK2 Background
Mitogen-activated protein kinase 9 (MAPK9), also well known as c-Jun N-terminal kinase (JNK2), is a member of MAP kinase subfamily belonging to the protein kinase superfamily. MAPK9 responds to activation by environmental stress and pro-inflammatory cytokines by phosphorylating a number of transcription factors, such as c-Jun and ATF2. The crystal structure of human JNK2 complexed with an indazole inhibitor by applying a high-throughput protein engineering and surface-site mutagenesis approach. A novel conformation of the activation loop is observed, which is not compatible with its phosphorylation by upstream kinases. This activation inhibitory conformation of JNK2 is stabilized by the MAP kinase insert that interacts with the activation loop in an induced-fit manner. It suggest that the MAP kinase insert of JNK2 plays a role in the regulation of JNK2 activation, possibly by interacting with intracellular binding partners. JNK2 deficiency leads to reduced c-Jun degradation, thereby augmenting c-Jun levels and cellular proliferation, and suggests that JNK2 is a negative regulator of cellular proliferation in multiple cell types. JNK2 prevents replicative stress by coordinating cell cycle progression and DNA damage repair mechanisms. JNK2 blocks the ubiquitination of tumor suppressor p53, and thus increases the stability of p53 in nonstressed cells. JNK2 negatively regulates antigen-specific CD8+ T cell expansion and effector function, and thus selectively blocking JNK2 in CD8+ T cells may potentially enhance anti-tumor immune response. Lack of JNK2 expression was associated with higher tumor aneuploidy and reduced DNA damage response. Additionally,the JNK2 protein could be a novel therapeutic target in dry eye disease, and may provide a novel target for prevention of vascular disease and atherosclerosis.
JNK2 Related Studies
- Sabapathy K, et al. (2004) JNK2: a negative regulator of cellular proliferation. Cell Cycle. 3(12): 1520-3.
- Tao J, et al. (2007) JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response. Eur J Immunol. 37(3): 818-29.
- Shaw D, et al. (2008) The crystal structure of JNK2 reveals conformational flexibility in the MAP kinase insert and indicates its involvement in the regulation of catalytic activity. J Mol Biol. 383(4): 885-93.
- Osto E, et al. (2008) c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. 118(20): 2073-80.
- De Paiva CS, et al. (2009) Essential role for c-Jun N-terminal kinase 2 in corneal epithelial response to desiccating stress. Arch Ophthalmol. 127(12): 1625-31.
- Chen P, et al. (2010) Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model. PLoS One. 5(5): e10443.
